bpc 157 peptide therapy BPC-157 BPC-157 Peptide Therapy | Regenerative

The physician evaluates the extent of infection, rules out abscess, and determines outpatient IM antibiotic therapy is appropriate

Typical GLOW dosing uses pre-mixed blends at 0.9 to 1.8 mg daily subcutaneously for six to eight weeks with a 90 day maximum continuous use followed by 30 day washout period

Fully achieved reduction of severe lesions in the brain, heart, lungs, liver, kidneys, and gastrointestinal tract reduced thrombosis in both veins and arteries, peripherally and centrally, and fully abrogated intracranial (superior sagittal sinus), portal, and caval hypertension and aortal hypotension may be regarded as a proof of concept

Most peptide protocols use 12 mL per reconstitution